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Personalized medicine is expected to revo-
lutionize health care delivery in the next
decade. I believe that targeted proteomic diag-
nostics and therapeutics will be the basis of
personalized molecular medicine. 
Clinical proteomics is the application of
proteomic techniques to the field of medicine.
The application of clinical proteomic research
is growing rapidly in the field of biomarker
discovery, especially in the area of cancer diag-
nostics. Because most diseases like cancer are
complex, it is unlikely that a single biomarker
could be used successfully for the early detec-
tion of cancer. It is likely that a multiple
marker panel would be required for cancer
diagnostics. Recent advances in proteomics
and bioinformatics technologies, such as mass
spectrometry (MS) and affinity-based meth-
ods, such as protein microarrays, have been
used successfully to detect disease-associated
biomarkers in complex biological specimens,
for example, cell lysates, serum, plasma, and
other body fluids. Extensive validation will be
needed to transform these biomarkers into tar-
geted clinical use.
Clinical proteomics holds the potential of
“taking a snapshot” of the total protein com-
plement of a cell, or body fluid, and identify-
ing proteins as potential biomarkers for the
differentiation of disease and health. For suc-
cessful biomarker discovery, validation, and
translation of these biomarkers into clinical
practices, many issues need to be addressed
including study design, bioinformatics, speci-
men acquisition, handling, quality control,
standard operating procedures, and good lab-
oratory practices (1). 
The majority of the biomarker discovery is
focused on the proteomic exploration of body
fluids, as these specimens are information rich
and more accessible. Unlike other tissues,
blood (plasma or serum) is the most complex
human-derived proteome. In addition to con-
taining proteins specific to blood, it also con-
tains proteins released, either through leakage,
injury or other factors, from other tissues in the
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body. The extreme dynamic range in plasma
protein concentrations of various proteins poses
a challenge to proteomic analysis (2).
A good understanding of how preanalytical
variables affect test results is important 
in biomarker research. Specimen handling,
whether sample collection, pipetting, or dilut-
ing, all contribute to preanalytical error. Exam-
ples are the different blood collection tubes (3),
coagulation times, storage conditions, or sample
type (whole blood, plasma, or serum). The
Human Proteome Organization (HUPO) estab-
lished a Specimen Committee in 2002 to study
and address many of these issues. A report from
this committee was published recently (4).
Another source of variation is biological varia-
tion (i.e., between-subject variation and within-
subject variation). For any individual, many
analytes fluctuate based on the time of day, fast-
ing state, or age. Although these fluctuations
may not be clinically relevant, they do add an
additional level of complexity in elucidating
disease-induced protein changes from changes
caused by biorhythmic fluctuations.
Serum/plasma contains roughly 60–80 mg
of protein per milliliter. It is estimated that
there are more than 10,000 proteins commonly
found in serum—most of them are present in
very low concentrations. Roughly 22 high-
abundant proteins—albumin, immunoglobulin,
haptoglobin, and transferrin, to name a few—
comprise approx 97% of the protein content of
serum. The remaining 3% of proteins are pre-
sent in low concentrations and are referred to
as low-abundant proteins. Most attempts to
separate/remove high-abundant proteins from
serum have focused on albumin, the most
abundant serum protein, which comprises
45–55% of all serum proteins, and immuno-
globulin, which comprises approx 15% of all
serum proteins. Eliminating or reducing these
two high-abundant proteins will remove
approx 60% of the total serum proteins and
make it easier to analyze lower-abundant
proteins. Recently, devices such as protein
depletion columns have been developed with
antibodies against the most abundant 6, 12, or
22 proteins. One should be aware of the
potential of removing other proteins of interest
along with these high-abundant proteins. Fur-
thermore, one should assess not only the effi-
ciency of the depletion method, but also the
reproducibility of this procedure. In addition
to selecting an effective fractionation method
that will remove high-abundant proteins, an
equally important issue is selecting the
methodology for biomarker discovery. One
common approach to the application of 
MS to biomarker discovery is the use of pro-
tein profiling from matrix-assisted laser des-
orption/ionization (MALDI)-time-of-flight
(TOF) or surface-enhanced laser desorption/
ionization (SELDI)-TOF MS as a “protein 
fingerprint” to identify a diseased state, fol-
lowed by the identification of specific pro-
teins as potential diagnostic biomarkers. The
other approach is to digest proteins into pep-
tides for liquid chromatography MS or
MALDI-TOF MS for analysis. Once peptides
of interest are identified, they could be traced
back to the proteins. With either one of these
two approaches, sophisticated bioinformatics
tools are needed.
The enormous amount of data produced
during proteomic analysis, coupled with the
inherent variation in the instrumentation used,
require the utilization of sound experimental
design, proper calibration of instruments, and
appropriate bioinformatics methods in order
to generate good quality data from which
valid conclusions can be drawn (5). In bio-
marker research, samples are generally col-
lected from multiple sites and randomly
divided into a discovery (training) data set
and a validation (testing) data set. Differences
in collection practices, sample handling, or
storage conditions will differ between institu-
tions and, as such, may influence the proteins
present in a given sample. For results to be
meaningful, a sufficiently large number of
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collection sites must be employed and the
sample population must be diverse so as to
best represent the target population of inter-
est. Because both data sets are derived from
the same-pooled samples, it will naturally
follow that the discovery set will represent
the validation set. This might result in artifi-
cially high performance (i.e., sensitivity and
specificity). An alternative approach that is
employed in our laboratories is to use each
sites data sets separately (6). For example,
potential biomarkers discovered from one site
would then be cross-compared and validated
using other sites data sets. This type of
model mimics the multicenter validation
process that all clinically useful biomarkers
must conform with prior to clinical use. An
example of the success of this approach can
be found in the work of Zhang et al. who
created two different discovery and valida-
tion cohorts using specimens from four dif-
ferent test sites (6). Candidate biomarkers
were cross-validated between discovery and
validation cohort sets, as well as against a
currently used cancer biomarker CA125.
Using such an approach, the authors suc-
cessfully identified three candidate proteins
that have the potential to distinguish ovar-
ian cancer from noncancer controls.
Finally, overwhelmed by the large number
of reports and at the same time the sharp
criticisms, “does it work?” has become a fre-
quently asked question. Specific experiments
and studies should be planned to answer
this question. Such studies will undoubtedly
provide invaluable information. For any
emerging technology, whether it works or
not at the beginning is not as important as
understanding whether the physical princi-
ples behind the new technology are sound.
If the answer is yes, the imperfections will
eventually be resolved. Right now we should
try to answer the more relevant question of
“will it work?” If the evidence supports it,
we then should let scientific discovery and
technological innovation have the opportu-
nity to proceed (7). 
Clinical proteomics is the most exciting clin-
ical laboratory science of the 21st century. In the
past year, we have witnessed significant com-
mitments from private and public sectors in the
research and development of clinical proteo-
mics. Recently, the National Cancer Institute
announced a $104 million program for clinical
proteomics technology assessment for cancer.
In the private sector, the pharmaceutical indus-
try has been the leader in using proteomic
approach for biomarkers and drug discovery.
Diagnostic industries have begun to explore
opportunities in clinical proteomics. In the end,
clinical laboratories and, ultimately, patients
will benefit from these advances in proteomics.
Clinical Proteomics is in the unique position
to provide a scholarly forum for novel scien-
tific research in the field of translational 
proteomics, with special emphasis on the
application of proteomic technology to all
aspects of clinical investigations including aca-
demic, clinical laboratory, pharmaceutical, and
diagnostic industries. We have a strong edito-
rial team of leading scientists in the field of
clinical proteomics with four associate editors,
Robert J. Cotter, PhD, Eleftherios P. Diamandis,
MD, PhD, Samir Hanash, MD, PhD, and Lance
Liotta, MD, PhD, and the entire editorial board
members. We expect that Clinical Proteomics
will be the authoritative forum for this field.
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